Anti-diabetogenic effect of the human amylin analogue, pramlintide, in Type 1 diabetes is not mediated by GLP-1.

Bo Ahrén, N Adner, J Svartberg, E Petrella, J J Holst, M K Gutniak

Research output: Contribution to journal › Letter › peer-review

Subject classification (UKÄ)

This output contributes to the following UN Sustainable Development Goals (SDGs)

@article{ee80cb2b17db4c9189573eadfd700a7f,

title = "Anti-diabetogenic effect of the human amylin analogue, pramlintide, in Type 1 diabetes is not mediated by GLP-1.",

author = "Bo Ahr{\'e}n and N Adner and J Svartberg and E Petrella and Holst, {J J} and Gutniak, {M K}",

year = "2002",

doi = "10.1046/j.1464-5491.2002.00657_1.x",

language = "English",

volume = "19",

pages = "790--792",

journal = "Diabetic Medicine",

issn = "1464-5491",

publisher = "Wiley-Blackwell",

number = "9",

}

TY - JOUR

T1 - Anti-diabetogenic effect of the human amylin analogue, pramlintide, in Type 1 diabetes is not mediated by GLP-1.

AU - Ahrén, Bo

AU - Adner, N

AU - Svartberg, J

AU - Petrella, E

AU - Holst, J J

AU - Gutniak, M K

PY - 2002

Y1 - 2002

U2 - 10.1046/j.1464-5491.2002.00657_1.x

DO - 10.1046/j.1464-5491.2002.00657_1.x

M3 - Letter

SN - 1464-5491

VL - 19

SP - 790

EP - 792

JO - Diabetic Medicine

JF - Diabetic Medicine

IS - 9

ER -